MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

Home・Aktien・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Geschlossen

1.32 1.54

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.3

Max

1.33

Schlüsselkennzahlen
By Trading Economics
Einkommen	17M -26M
Angestellte	171
EBITDA	19M -23M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+129.01% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	26. Feb. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-24M 79M
Vorheriger Eröffnungskurs	-0.22
Vorheriger Schlusskurs	1.32

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

1.43 / 1.6 Unterstützung & Widerstand

Pliant Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

9. Jan. 2026, 22:18 UTC

Market Talk

Changes Needed for Exxon Mobil to Return to Venezuela -- Market Talk

9. Jan. 2026, 21:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

9. Jan. 2026, 21:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Basic Materials Roundup: Market Talk

9. Jan. 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9. Jan. 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

9. Jan. 2026, 21:43 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

These Stocks Moved the Most Today: Oklo, Vistra, Opendoor, Intel, GM, Revolution Medicines, Tilray, and More -- Barrons.com

9. Jan. 2026, 20:39 UTC

Market Talk

GE Vernova Seen With Rising Concern of Overcapacity -- Market Talk

9. Jan. 2026, 20:38 UTC

Market Talk

U.S. Natural Gas Falls on Loose Supply Outlook -- Market Talk

9. Jan. 2026, 20:36 UTC

Akquisitionen, Fusionen, Übernahmen

Cathie Wood's ARK Invest Takes a New Stake in Broadcom -- and Sold Another Hot Stock -- Barrons.com

9. Jan. 2026, 20:30 UTC

Market Talk

Oil Makes Weekly Gains in Geopolitically Driven Trade -- Market Talk

9. Jan. 2026, 20:15 UTC

Market Talk

Chevron Seen With Modest Opportunity to Boost Venezuela Oil Production -- Market Talk

9. Jan. 2026, 20:07 UTC

Market Talk

Global Equities Roundup: Market Talk

9. Jan. 2026, 20:07 UTC

Market Talk

Goldman Sachs' Pivot from Consumer Lending Seen as Positive -- Market Talk

9. Jan. 2026, 19:58 UTC

Akquisitionen, Fusionen, Übernahmen

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

9. Jan. 2026, 19:42 UTC

Market Talk

Adobe Seen With Weak Competitive Position Compared to Rivals -- Market Talk

9. Jan. 2026, 19:38 UTC

Akquisitionen, Fusionen, Übernahmen

Wolters Kluwer Acquires StandardFusion >WTKWY

9. Jan. 2026, 19:31 UTC

Ergebnisse

Qualcomm Stock Falls After Downgrade. The Apple Supplier Has an iPhone Problem. -- Barrons.com

9. Jan. 2026, 19:28 UTC

Ergebnisse

Apple Stock Set to Break Brutal Losing Streak. Why It Remains Evercore's 'Top Pick.' -- Barrons.com

9. Jan. 2026, 18:30 UTC

Market Talk

U.S. Oil Rig Count Falls by 3 to 409 -- Market Talk

9. Jan. 2026, 18:23 UTC

Market Talk

Reports of Canada Oil Sector's Demise Are Premature -- Market Talk

9. Jan. 2026, 17:20 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Basic Materials Roundup: Market Talk

9. Jan. 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9. Jan. 2026, 17:19 UTC

Market Talk

Energy Prices Not Seen Supporting More Drilling -- Market Talk

9. Jan. 2026, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9. Jan. 2026, 17:07 UTC

Market Talk

McDonald's Promotions Appear Successful -- Market Talk

9. Jan. 2026, 17:06 UTC

Market Talk

Oil Futures on Track for Weekly Gains -- Market Talk

9. Jan. 2026, 17:05 UTC

Ergebnisse

Stocks Sail Past Jobs Data, Tariff Opinion Delay. Earnings Season Looms. -- Barrons.com

9. Jan. 2026, 16:57 UTC

Market Talk

Energy Activity Tumbles in 4Q, KC Fed Survey Finds -- Market Talk

9. Jan. 2026, 16:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9. Jan. 2026, 16:46 UTC

Market Talk

Dollar Could Stay Steady For Now, More Likely to Fall Than Rise -- Market Talk

Peer-Vergleich

Kursveränderung

Pliant Therapeutics Inc Prognose

Kursziel

By TipRanks

129.01% Vorteil

12-Monats-Prognose

Durchschnitt 3 USD 129.01%

Hoch 4 USD

Tief 2 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pliant Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

4 ratings

Buy

Halten

Sell

Basierend auf 4 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pliant Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.43 / 1.6Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.